Jazz Pharmaceuticals plc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
JAZZ Nasdaq 2830 www.jazzpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jazz Pharmaceuticals plc

One Jazz Pharmaceuticals Insider Raised Their Stake In The Previous Year - Jul 2nd, 2025 7:49 am
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer - Jul 2nd, 2025 3:21 am
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results - Jul 2nd, 2025 12:46 am
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - Jul 1st, 2025 6:31 am
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q1 Earnings Call - Jun 27th, 2025 3:22 am
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Jun 11th, 2025 5:59 pm
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer - Jun 10th, 2025 5:05 am
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - Jun 9th, 2025 4:00 pm
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Jun 5th, 2025 9:30 am
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - Jun 2nd, 2025 2:05 pm
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - Jun 2nd, 2025 10:35 am
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - May 29th, 2025 5:30 am
3 of Wall Street’s Favorite Stocks with Mounting Challenges - May 25th, 2025 10:34 pm
Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board - May 23rd, 2025 4:02 am
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - May 21st, 2025 2:30 pm
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook - May 19th, 2025 7:53 am
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point - May 15th, 2025 4:58 am
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - May 13th, 2025 9:31 pm
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - May 13th, 2025 7:16 am
Biotech Alert: Searches spiking for these stocks today - May 10th, 2025 9:55 am